ArticleDiscover oncology2025
Identification of potential bladder cancer drug targets through Mendelian randomization and molecular docking.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Bladder cancer is a common and lethal malignancy with high treatment costs due to frequent recurrence and prolonged therapy. Despite therapeutic advances, many patients develop drug-resistant metastatic disease, underscoring the need for new treatments. Using the STROBE-MR guidelines, we performed Mendelian randomization with cis- expression quantitative trait loci (eQTLs) from the eQTLGen Consortium (n = 31,684) as exposures. Two independent cohorts served as discovery and replication sets for target identification. Drug prediction and molecular docking were applied to validate the targets. Twelve significant drug targets were identified. Phenome-wide association study revealed additional associations of NDST1 and HMGCR with proteomic traits and health service use, respectively. Molecular docking confirmed strong binding for available protein structures. Our study identified 12 promising drug targets for bladder cancer and suggests that MR-based prioritization may improve clinical trial success and reduce development costs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.